Skip to main content
Fig. 4 | Human Genomics

Fig. 4

From: Integrating rare genetic variants into pharmacogenetic drug response predictions

Fig. 4

Evaluation of the role of rare genetic variants for voriconazole and olanzapine pharmacokinetics. a Schematic depiction of key events in voriconazole metabolism. See www.pharmgkb.org/pathway/PA166160640 for further information. b Overview of the aggregated frequencies of common (MAF ≥ 1%, blue) and rare deleterious genetic variants (MAF < 1%, red) in genes involved in voriconazole metabolism. Values next to the columns indicate the relative contribution of rare genetic variants. c Stacked column plot showing the aggregated frequency of deleterious rare variants of potential relevance for voriconazole metabolism. d Schematic showing steps involved in the pharmacokinetics of the antipsychotic olanzapine. See www.pharmgkb.org/pathway/PA166165056 for further information. e Overview of the aggregated frequencies of common (MAF ≥ 1%, blue) and rare deleterious genetic variants (MAF < 1%, red) in genes implicated in olanzapine clearance. Values next to the columns indicate the relative contribution of rare genetic variants. f The aggregated frequency of deleterious rare variants of potential relevance for olanzapine metabolism is shown

Back to article page
\